首页/数据集/TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer

TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer

NIAID Data Ecosystem2026-05-01 收录

非小细胞肺癌免疫治疗

CAR-T细胞疗法

数据链接：

https://figshare.com/articles/dataset/TABLE_1_from_Rejuvenated_iPSC-derived_GD2-directed_CART_Cells_Harbor_Robust_Cytotoxicity_Against_Small_Cell_Lung_Cancer/25382561 数据链接链接失效反馈

官方服务：

资源简介：

Primer and probe information

应用场景：

创建时间：

2024-03-11

CAR-T细胞疗法

免疫信号通路

RNAseq analysis of human CAR-Tregs, bearing CD28 or 4-1BB as a costimulatory domains, initially isolated (before engineering) from peripheral blood of healthy donors Overall design: CD25+ naive Tregs

NIAID Data Ecosystem100

De novo designed receptor transmembrane domains enhance CAR-T cytotoxicity and attenuate cytokine release

CAR-T细胞疗法

跨膜结构域

De novo designed receptor transmembrane domains enhance CAR-T cytotoxicity and attenuate cytokine release

NIAID Data Ecosystem30

Dataset from A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

非小细胞肺癌免疫治疗

III期临床试验

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-b

NIAID Data Ecosystem10

Table_2_Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer.docx

非小细胞肺癌免疫治疗

生存期替代终点

BackgroundThe combination of immune checkpoint inhibitors (ICIs) and chemotherapy is known to improve overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). ICIs have

NIAID Data Ecosystem40

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors

CAR-T细胞疗法

药物血液毒性

Cytopenia is one of the most common adverse events following the CAR-T cell infusion, affecting the quality of life and potentially leading to life-threatening bleeding and infection. This study aimed

Taylor & Francis Group2025-09-08 更新20

TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer

资源简介：

相关数据集